Clinical Trial

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 20, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to determine if there is a greater effect to patients with advanced pulmonary arterial hypertension (PAH) by using a combination of two drugs, Treprostinil and Riociquat versus Treprostinil alone
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2019-08-19.
Trial Details
NCT Number NCT04062565
Lead Sponsor University of Arizona
Conditions Pulmonary Arterial Hypertension
Enrollment 20 participants
Start Date 2019-03-25
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-20